Annual long term liabilities:
$2.56B+$956.60M(+59.70%)Summary
- As of today (May 19, 2025), VRTX annual total long term liabilities is $2.56 billion, with the most recent change of +$956.60 million (+59.70%) on December 31, 2024.
- During the last 3 years, VRTX annual long term liabilities has risen by +$1.37 billion (+114.95%).
- VRTX annual long term liabilities is now at all-time high.
Performance
VRTX Long term liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly long term liabilities:
$2.60B+$42.00M(+1.64%)Summary
- As of today (May 19, 2025), VRTX quarterly total long term liabilities is $2.60 billion, with the most recent change of +$42.00 million (+1.64%) on March 31, 2025.
- Over the past year, VRTX quarterly long term liabilities has increased by +$1.03 billion (+65.15%).
- VRTX quarterly long term liabilities is now -1.34% below its all-time high of $2.64 billion, reached on September 30, 2024.
Performance
VRTX quarterly long term liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Long term liabilities Formula
Long-Term Liabilities = Long-Term Debt + Deferred Tax Liabilities + Pension Liabilities + Other Long-Term Liabilities
VRTX Long term liabilities Trends
PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
---|---|---|
1 y1 year | +59.7% | +65.2% |
3 y3 years | +115.0% | +122.5% |
5 y5 years | +184.8% | +191.3% |
VRTX Long term liabilities Highs & Lows
PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
---|---|---|---|---|---|
3 y | 3-year | at high | +115.0% | -1.3% | +143.7% |
5 y | 5-year | at high | +184.8% | -1.3% | +191.3% |
alltime | all time | at high | >+9999.0% | -1.3% | >+9999.0% |
VRTX Long term liabilities History
Date | Annual | Quarterly |
---|---|---|
Mar 2025 | - | $2.60B(+1.6%) |
Dec 2024 | $2.56B(+59.7%) | $2.56B(-2.9%) |
Sep 2024 | - | $2.64B(+45.6%) |
Jun 2024 | - | $1.81B(+14.9%) |
Mar 2024 | - | $1.57B(-1.7%) |
Dec 2023 | $1.60B(+7.1%) | $1.60B(-0.7%) |
Sep 2023 | - | $1.61B(+5.7%) |
Jun 2023 | - | $1.53B(+0.7%) |
Mar 2023 | - | $1.52B(+1.3%) |
Dec 2022 | $1.50B(+25.7%) | $1.50B(+40.1%) |
Sep 2022 | - | $1.07B(-2.3%) |
Jun 2022 | - | $1.09B(-6.5%) |
Mar 2022 | - | $1.17B(-1.8%) |
Dec 2021 | $1.19B(+0.3%) | $1.19B(+1.4%) |
Sep 2021 | - | $1.17B(-1.3%) |
Jun 2021 | - | $1.19B(-0.2%) |
Mar 2021 | - | $1.19B(+0.3%) |
Dec 2020 | $1.19B(+32.2%) | $1.19B(+2.0%) |
Sep 2020 | - | $1.16B(+29.6%) |
Jun 2020 | - | $898.49M(+0.6%) |
Mar 2020 | - | $892.80M(-0.6%) |
Dec 2019 | $898.39M(+30.1%) | $898.39M(+3.0%) |
Sep 2019 | - | $872.26M(+23.9%) |
Jun 2019 | - | $704.29M(-1.3%) |
Mar 2019 | - | $713.33M(+3.3%) |
Dec 2018 | $690.40M(-0.9%) | $690.40M(-0.5%) |
Sep 2018 | - | $693.85M(+0.1%) |
Jun 2018 | - | $693.20M(-0.2%) |
Mar 2018 | - | $694.84M(-0.2%) |
Dec 2017 | $696.45M(-9.1%) | $696.45M(+1.8%) |
Sep 2017 | - | $684.34M(-13.7%) |
Jun 2017 | - | $792.96M(+2.4%) |
Mar 2017 | - | $774.11M(+1.1%) |
Dec 2016 | $766.06M(-14.8%) | $766.06M(+12.9%) |
Sep 2016 | - | $678.46M(-10.4%) |
Jun 2016 | - | $757.28M(-7.6%) |
Mar 2016 | - | $819.67M(-8.8%) |
Dec 2015 | $898.79M(+3.3%) | $898.79M(-8.5%) |
Sep 2015 | - | $982.30M(+3.2%) |
Jun 2015 | - | $952.03M(+10.0%) |
Mar 2015 | - | $865.85M(-0.5%) |
Dec 2014 | $870.24M(+54.1%) | $870.24M(-0.9%) |
Sep 2014 | - | $878.00M(+50.7%) |
Jun 2014 | - | $582.58M(-1.7%) |
Mar 2014 | - | $592.73M(+4.9%) |
Dec 2013 | $564.81M(-50.1%) | $564.81M(-22.2%) |
Sep 2013 | - | $726.19M(+4.8%) |
Jun 2013 | - | $693.23M(-33.8%) |
Mar 2013 | - | $1.05B(-7.4%) |
Dec 2012 | $1.13B(+28.0%) | $1.13B(+8.0%) |
Sep 2012 | - | $1.05B(+6.7%) |
Jun 2012 | - | $981.54M(+11.1%) |
Mar 2012 | - | $883.45M(-0.0%) |
Dec 2011 | $883.46M(+18.3%) | $883.46M(+8.8%) |
Sep 2011 | - | $812.20M(-2.7%) |
Jun 2011 | - | $834.95M(+14.3%) |
Mar 2011 | - | $730.62M(-2.2%) |
Dec 2010 | $746.69M(+30.0%) | $746.69M(-19.5%) |
Sep 2010 | - | $927.17M(+73.4%) |
Jun 2010 | - | $534.69M(-5.9%) |
Mar 2010 | - | $568.15M(-1.1%) |
Dec 2009 | $574.26M(+9.4%) | $574.26M(-21.7%) |
Sep 2009 | - | $733.38M(+39.1%) |
Jun 2009 | - | $527.14M(-22.4%) |
Mar 2009 | - | $679.73M(+29.5%) |
Dec 2008 | $525.04M | $525.04M(-2.3%) |
Sep 2008 | - | $537.20M(-2.0%) |
Jun 2008 | - | $547.99M(+33.0%) |
Date | Annual | Quarterly |
---|---|---|
Mar 2008 | - | $411.93M(+214.7%) |
Dec 2007 | $130.90M(-20.5%) | $130.90M(-4.7%) |
Sep 2007 | - | $137.41M(-4.3%) |
Jun 2007 | - | $143.58M(-9.8%) |
Mar 2007 | - | $159.21M(-3.3%) |
Dec 2006 | $164.63M(-21.4%) | $164.63M(-29.3%) |
Sep 2006 | - | $232.89M(-31.9%) |
Jun 2006 | - | $341.75M(+63.1%) |
Mar 2006 | - | $209.50M(-0.0%) |
Dec 2005 | $209.58M(-41.2%) | $209.58M(-29.1%) |
Sep 2005 | - | $295.45M(-12.1%) |
Jun 2005 | - | $335.96M(-2.5%) |
Mar 2005 | - | $344.55M(-3.3%) |
Dec 2004 | $356.27M(-9.2%) | $356.27M(-2.6%) |
Sep 2004 | - | $365.60M(-2.8%) |
Jun 2004 | - | $376.31M(-3.8%) |
Mar 2004 | - | $391.25M(-0.3%) |
Dec 2003 | $392.50M(+5.4%) | $392.50M(+0.2%) |
Sep 2003 | - | $391.57M(+1.1%) |
Jun 2003 | - | $387.42M(+1.0%) |
Mar 2003 | - | $383.75M(+3.0%) |
Dec 2002 | $372.54M(+4.0%) | $372.54M(+2.3%) |
Sep 2002 | - | $364.07M(+0.7%) |
Jun 2002 | - | $361.51M(+0.5%) |
Mar 2002 | - | $359.85M(+0.5%) |
Dec 2001 | $358.23M(+0.3%) | $358.23M(+1.1%) |
Sep 2001 | - | $354.19M(+2.2%) |
Jun 2001 | - | $346.63M(-0.1%) |
Mar 2001 | - | $346.97M(-2.9%) |
Dec 2000 | $357.27M(+7512.8%) | $357.27M(+2.6%) |
Sep 2000 | - | $348.12M(+94.9%) |
Jun 2000 | - | $178.62M(-0.3%) |
Mar 2000 | - | $179.16M(+3717.5%) |
Dec 1999 | $4.69M(-33.0%) | $4.69M(-9.8%) |
Sep 1999 | - | $5.20M(-10.3%) |
Jun 1999 | - | $5.80M(-9.4%) |
Mar 1999 | - | $6.40M(-8.6%) |
Dec 1998 | $7.00M(+18.6%) | $7.00M(-7.9%) |
Sep 1998 | - | $7.60M(+10.1%) |
Jun 1998 | - | $6.90M(+11.3%) |
Mar 1998 | - | $6.20M(+5.1%) |
Dec 1997 | $5.90M(+5.4%) | $5.90M(+9.3%) |
Sep 1997 | - | $5.40M(0.0%) |
Jun 1997 | - | $5.40M(+1.9%) |
Mar 1997 | - | $5.30M(-5.4%) |
Dec 1996 | $5.60M(+14.3%) | $5.60M(+27.3%) |
Sep 1996 | - | $4.40M(-2.2%) |
Jun 1996 | - | $4.50M(+2.3%) |
Mar 1996 | - | $4.40M(-10.2%) |
Dec 1995 | $4.90M(+4.3%) | $4.90M(0.0%) |
Sep 1995 | - | $4.90M(-2.0%) |
Jun 1995 | - | $5.00M(0.0%) |
Mar 1995 | - | $5.00M(+6.4%) |
Dec 1994 | $4.70M(+11.9%) | $4.70M(+2.2%) |
Sep 1994 | - | $4.60M(+4.5%) |
Jun 1994 | - | $4.40M(+15.8%) |
Mar 1994 | - | $3.80M(-9.5%) |
Dec 1993 | $4.20M(+31.3%) | $4.20M(+5.0%) |
Sep 1993 | - | $4.00M(+5.3%) |
Jun 1993 | - | $3.80M(+11.8%) |
Mar 1993 | - | $3.40M(+6.3%) |
Dec 1992 | $3.20M(+45.5%) | $3.20M(0.0%) |
Sep 1992 | - | $3.20M(+6.7%) |
Jun 1992 | - | $3.00M(+30.4%) |
Mar 1992 | - | $2.30M(+4.5%) |
Dec 1991 | $2.20M(-8.3%) | $2.20M(-4.3%) |
Sep 1991 | - | $2.30M(-8.0%) |
Jun 1991 | - | $2.50M(+4.2%) |
Dec 1990 | $2.40M | $2.40M |
FAQ
- What is Vertex Pharmaceuticals Incorporated annual total long term liabilities?
- What is the all time high annual long term liabilities for Vertex Pharmaceuticals Incorporated?
- What is Vertex Pharmaceuticals Incorporated annual long term liabilities year-on-year change?
- What is Vertex Pharmaceuticals Incorporated quarterly total long term liabilities?
- What is the all time high quarterly long term liabilities for Vertex Pharmaceuticals Incorporated?
- What is Vertex Pharmaceuticals Incorporated quarterly long term liabilities year-on-year change?
What is Vertex Pharmaceuticals Incorporated annual total long term liabilities?
The current annual long term liabilities of VRTX is $2.56B
What is the all time high annual long term liabilities for Vertex Pharmaceuticals Incorporated?
Vertex Pharmaceuticals Incorporated all-time high annual total long term liabilities is $2.56B
What is Vertex Pharmaceuticals Incorporated annual long term liabilities year-on-year change?
Over the past year, VRTX annual total long term liabilities has changed by +$956.60M (+59.70%)
What is Vertex Pharmaceuticals Incorporated quarterly total long term liabilities?
The current quarterly long term liabilities of VRTX is $2.60B
What is the all time high quarterly long term liabilities for Vertex Pharmaceuticals Incorporated?
Vertex Pharmaceuticals Incorporated all-time high quarterly total long term liabilities is $2.64B
What is Vertex Pharmaceuticals Incorporated quarterly long term liabilities year-on-year change?
Over the past year, VRTX quarterly total long term liabilities has changed by +$1.03B (+65.15%)